In response to Thailand’s decision to issue compulsory licenses for Kaletra and for Plavix, effectively bypassing their patents by purchasing […]

Welcome to the April 10, 2007 edition of Carnival of Biotechnology. Finance and business development On Pharma presents a report

Following up on the success of “Building Biotechnology” (www.BuildingBiotechnology.com), I’m in the late stages of assembling a more advanced follow-up

Genentech is investing $140mm in a new biologic manufacturing plant in Singapore. The first commercial-scale microbial fermentation plant in Singapore,

I touched briefly on the Medimmune v. Genentech case in a previous Carnival of Biotechnology, but I didn’t go into

The latest Carnival of Biotechnology is up at Baby Biotechs. Great job, Brian! For more information, see the Carnival of

Just came across an article on diabetics going to Mexico to receive pig xenotransplants. Unlike other forms of medical tourism,

This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the

If there’s one sure rule about private equity, it is that there are no rules about private equity! Venture capitalists